# ARCTURUS THERAPEUTICS HOLDINGS INC. (ARCT) · Edgar & Edgarette company card

> Arcturus Therapeutics Holdings (ARCT) saw revenue fall 46.1% in FY2025 to $82 million, operating margin -93.0% against a -3.8% median for pharmaceutical preparations, equity 78.9% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1768224 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/ARCT) · [JSON](https://www.pops4.com/boards/company/ARCT.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $82M |
| Revenue growth, 1 year | -46.1% |
| Revenue growth per year | 60.5% |
| Operating margin | -93.0% (prior year -62.8%) |
| Net margin | -80.2% |
| Operating cash flow | −$74M |
| Capital spending | $230,000 |
| Free cash flow | −$75M |
| Cash | $231M |
| Long-term debt | — |
| Total assets | $271M |
| Total equity | $214M |
| Equity ÷ assets | 78.9% |
| Return on equity | -30.7% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: 0.81 (distress zone)
- Piotroski F: 2 of 9 (weak)
- Health Harbor boat: Rotting at the dock · four or more warning signs · slow and jumpy: growing slower than its size class, with revenue that swings more; operating cash flow was negative; operating loss: a margin of -93.0% in FY2025; revenue is hard to predict: its 80% range is ±61%
- Cash Compass: Fading · slow and jumpy, lagging its peers

## Edgarette's reading

Exposure: revenue $82.0M (FY2025). Experience: revenue down 46.1% on the year, up 60.5% a year over 4 years; operating margin -93.0%, down from -62.8%. Soundness: equity 78.9% of assets, return on equity -30.7%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $24.5M and $101.9M next year (method v4.1: its own 5-year record of growth weighed at 57% against $50M–100M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $25.8M to $97.0M. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -93.0% against a -3.8% median; growth -46.1% against 13.7%.

Range logged 2026-11-01, receipt 8f678eab313c333a, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 2, latest 2026-05-07 ([filing](https://www.sec.gov/Archives/edgar/data/1768224/000119380526000573/0001193805-26-000573-index.htm))

## Recent filings

- 8-K · filed 2026-11-16 · 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1768224/000119380526001485/0001193805-26-001485-index.htm)
- 10-Q · filed 2026-11-05 · [filing](https://www.sec.gov/Archives/edgar/data/1768224/000119312526449901/0001193125-26-449901-index.htm)
- 8-K · filed 2026-11-05 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1768224/000119380526001439/0001193805-26-001439-index.htm)
- 8-K · filed 2026-09-23 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1768224/000119380526001277/0001193805-26-001277-index.htm)
- 8-K · filed 2026-08-25 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1768224/000119380526001130/0001193805-26-001130-index.htm)
- 10-Q · filed 2026-08-06 · [filing](https://www.sec.gov/Archives/edgar/data/1768224/000119312526338090/0001193125-26-338090-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001768224.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1768224

## Cite

POPS4, Edgar & Edgarette: ARCTURUS THERAPEUTICS HOLDINGS INC. (ARCT) company card, from the company's own SEC filings, accessed 2026-11-17, https://www.pops4.com/boards/company/ARCT. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.

